FDG PET/CT scan

DEVICE3 trials

Sponsors

Memorial Sloan Kettering Cancer Center, University of Pennsylvania, UNC Lineberger Comprehensive Cancer Center

Conditions

Bone MetastasesEstrogen Receptor Positive Breast CancerHead and Neck CancerMelanoma

Phase 2

Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker

CompletedNCT03089606

UNC Lineberger Comprehensive Cancer CenterMelanoma

Start: 2017-04-19End: 2023-07-01Updated: 2023-11-15

Unknown Phase

Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients

CompletedNCT00606294

Memorial Sloan Kettering Cancer CenterHead and Neck Cancer

Start: 2004-06-30End: 2023-06-09Updated: 2023-06-28

FDG PET/CT in Breast Cancer Bone Mets

Active, not recruitingNCT01996046

University of PennsylvaniaBone Metastases, Estrogen Receptor Positive Breast Cancer

Start: 2013-09-30End: 2026-07-31Target: 75Updated: 2025-09-02

Related Papers

Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanoma

OncoImmunology2023-04-2615 citations

High intratumoral tryptophan metabolism is a poor predictor of response to pembrolizumab (pembro) in metastatic melanoma (MM): Results from a prospective trial using baseline C11-labeled alpha-methyl tryptophan (C11-AMT) PET imaging for response prediction.

Journal of Clinical Oncology2020-05-204 citations

Abstract IA16: Midtreatment metabolic imaging as a biomarker of treatment response

Clinical Cancer Research2017-11-30

A personalized approach using hypoxia resolution to guide curative-intent radiation dose-reduction to 30 Gy: A novel de-escalation paradigm for HPV-associated oropharynx cancers (OPC).

Journal of Clinical Oncology2017-05-208 citations